Studies on the genetic abnormality and therapeutic effects and prognosis of multiple myeloma
Not Applicable
- Conditions
- Multiple myeloma
- Registration Number
- JPRN-UMIN000017005
- Lead Sponsor
- Clinical Hematlogy Study Group of National Hospital Organization (CHSGONHO)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 85
Inclusion Criteria
Not provided
Exclusion Criteria
1.Solitary plasmacytoma 2.Patients to use the insurance unapproved drugs to initial treatment 3.Patients that NHOMM study and MARBLE study are not registered
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of different genetic abnormalities detected by the MLPA method
- Secondary Outcome Measures
Name Time Method 1. Complete response rate with the initial treatment of different genetic abnormalities detected by MLPA method 2. Progression free survival with the initial treatment of different genetic abnormalities detected by MLPA method 3. Overall survival with the initial treatment of different genetic abnormalities detected by MLPA method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Prognostic impact specific cytogenetic abnormalities FISH multiple myeloma Japanese patient outcomes
Real-world treatment patterns outcomes multiple myeloma Japan observational study genetic stratification
Genetic biomarkers predicting therapeutic response prognosis multiple myeloma observational cohort studies
Therapeutic strategies high-risk multiple myeloma specific genetic abnormalities t(4;14) del(17p)
Molecular mechanisms linking genetic heterogeneity multiple myeloma clinical outcomes therapeutic resistance